Frontal Fibrosing alopecia Cicatricial alopecia
Conditions
Interventions
All patients will be submitted to a previous evaluation, in which photographic evaluation will be performed and measurements of the distance in centimeters between the glabella and the beginning of th
Procedure/surgery
E03.155.086.231
Sponsors
Hospital Universitário Walter Cantídeo Universidade Federal do Ceará
Hospital Universitário Walter Cantídeo Universidade Federal do Ceará
Eligibility
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with clinical diagnosis of Frontal fibrosing alopecia will be selected, including those with increased frontotemporal recess, associated or not with follicular papules and rarefaction of eyebrows; or histopathological diagnosis compatible with frontal fibrosing alopecia with follow up appointments at the Dermatology Department of Walter Cantideo University Hospital. Patients must be aged between 18 and 70 years old and must sign who the Informed Consent Form (ICF), with availability to attend periodic appointment evaluations.
Exclusion criteria
Exclusion criteria: Patients with the following conditions will be excluded: Pregnancy; Vitiligo, psoriasis or other skin diseases that present Koebner's phenomenon (development of chronic dermatosis in trauma areas); Active infections in the areas to be treated with microneedling; Presence of keloids in previous scars; History of allergy to topical or injectable anesthetic; Patients with psychiatric disorders or other clinical diseases that contraindicate the procedure; Patients who refuse to sign the Informed Consent Form (ICF) or who are unable to attend to periodic appointment evaluations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1: It is expected to observe a decrease in the disease progression,noted by the non-progression of the hair implantation recess (measured by the distance in centimeters between pre-established landmarks of the face and the beginning of the hair implantation line) by up to 3 months after the last procedure. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome 1: Improvement of the symptoms observed by the values of LPPAI score. Secondary outcome 2: It is expected to see improvement in clinical and dermatoscopic findings, verified through the comparison of photographic records by blinded external evaluators. Secondary outcome 3: It is expected to obtain clinical and epidemiological characterization of the patients, which will be obtained through clinical examination and application of specific questionnaires. Secondary outcome 4: It is expected to see an improvement in the patients' quality of life, which will be verified by comparing the DLQI questionnaire score obtained before the procedure, with the scores after each session, at week 4 and at week 12 after carrying out the procedure. | — |
Countries
Brazil
Contacts
Public ContactEmily;Xinaida Mourão Soares Lopes Furtado;Taligare Vasconcelos Lima
Hospital Universitário Walter Cantídeo Universidade Federal do Ceará;Hospital Universitário Walter Cantídeo Universidade Federal do Ceará
Outcome results
None listed